Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
View Patent ↗Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.
1. A pharmaceutical composition comprising a crystalline Compound (I):
wherein the crystalline Compound (I) has an X-ray powder diffraction pattern comprising peaks at approximately 15.0, 18.1, 20.3, 22.9, 24.0, 24.2, 26.3, 26.8, 35.2, and 37.4° 2θ and a melting point at 175.8° C.±5%; and
wherein the pharmaceutical composition comprises less than 10% by weight of any other crystalline Compound (I).
2. The pharmaceutical composition of claim 1 , wherein the crystalline compound comprises less than 5% by weight of any other crystalline Compound (I).
3. A pharmaceutical composition comprising a crystalline Compound (I):
wherein the crystalline Compound (I) has an X-ray powder diffraction comprising peaks at approximately 15.0, 18.1, 20.3, 22.9, 24.0, 24.2, 26.3, 26.8, 35.2, and 37.4° 2θ and a melting point at 175.8° C.±5%; and
wherein the pharmaceutical composition comprises less than 10% by weight of amorphous Compound (I).
4. The pharmaceutical composition of claim 3 , wherein the crystalline compound comprises less than 5% by weight of amorphous Compound (I).
5. A crystalline Compound (I):
which has an X-ray powder diffraction pattern comprising peaks at approximately 15.0, 18.1, 20.3, 22.9, 24.0, 24.2, 26.3, 26.8, 35.2, and 37.4° 2θ and a melting point at 175.8° C.±5%; and
wherein the crystalline Compound (I) is at least 99.5% pure as measured by HPLC.
6. The crystalline compound of claim 5 , wherein the crystalline Compound (I) is at least 99.6% pure as measured by HPLC.
7. The crystalline compound of claim 6 , wherein the crystalline Compound (I) is at least 99.7% pure as measured by HPLC.
8. The crystalline compound of claim 7 , wherein the crystalline Compound (I) is at least 99.8% pure as measured by HPLC.
9. The crystalline compound of claim 8 , wherein the crystalline Compound (I) is at least 99.9% pure as measured by HPLC.
10. The pharmaceutical composition of claim 1 , further comprising a pharmaceutically acceptable carrier.
11. An oral dosage form comprising a pharmaceutical composition of claim 1 .